Patient guide · RheumaView
Scleroderma & systemic sclerosis
Understand your diagnosis. Navigate care. Explore the evidence.
← Back to the topic map · Prepare for your visit
What does my diagnosis mean?
Systemic sclerosis can affect blood vessels, skin and internal organs. Your own pattern matters more than the name alone.
“Limited” and “diffuse” describe the distribution of skin thickening. They do not mean that all limited disease is mild or that everyone with diffuse disease follows the same course. Some people have systemic sclerosis without obvious skin thickening. Morphea, or localized scleroderma, is a separate condition.
An initial assessment looks for the organs affected and establishes a baseline. You may need tests even when you feel well because some changes can be silent. Ask for an explanation of your particular pattern, which findings are uncertain and what the next review is intended to check.
Raynaud phenomenon and early signs
Cold-triggered colour changes do not automatically mean systemic sclerosis. The surrounding findings determine whether further assessment is needed.
Raynaud attacks may cause fingers to become pale, blue or red, with numbness or discomfort. Many people with Raynaud do not develop a systemic autoimmune disease. Puffy fingers, skin tightening, fingertip sores, abnormal nailfold capillaries or particular antibodies can make a focused assessment useful.
Photograph a typical attack if it is safe to do so and note triggers, duration and recovery. Tell the clinician about new symptoms. A persistently pale or blue, very painful finger or a new ulcer needs prompt assessment; do not assume it is an ordinary attack just because you have had Raynaud for years.
Understanding antibodies and capillaroscopy
A blood test or nailfold image is one part of the assessment, not a complete diagnosis or prediction.
Anticentromere, Scl-70 and RNA polymerase III are examples of antibodies used in systemic sclerosis assessment. They can suggest which complications deserve particular attention, but they do not tell exactly what will happen to you. An unexpected positive result sometimes needs clarification of the test method and clinical context.
Capillaroscopy examines tiny blood vessels near the nails. It can help distinguish patterns of Raynaud and support a diagnosis. Ordinary variations and minor trauma can also affect the appearance. Ask what your result changes in your care; repeatedly checking antibody numbers is not a substitute for examining symptoms and organs.
Protecting fingers and caring for ulcers
Protect warmth and skin integrity, and report a sore or persistent circulation change early.
Keep your whole body warm, use comfortable gloves, avoid smoking and protect fingers from repeated injury. Warm cold hands gently; direct intense heat can burn numb skin. Discuss medicines that may worsen circulation. Prescribed vascular medicines work differently and can cause low blood pressure or other effects.
An ulcer needs an agreed wound-care plan and assessment for infection or poor blood supply. Do not cut away tissue or squeeze a deposit yourself. Severe ongoing pain, a finger that stays white or blue, black tissue, spreading redness, pus or fever needs urgent medical attention. If you take sildenafil or tadalafil, tell clinicians before using any nitrate medicine, including ointment.
Skin changes, calcium deposits and hand movement
Skin comfort, circulation and hand movement deserve attention alongside the internal organs.
Skin can feel swollen, tight, itchy or painful. Small calcium deposits may cause tender lumps or discharge through the skin; they are not simply caused by eating calcium. Report signs of infection and discuss any dietary change rather than restricting calcium yourself.
Moisturizing, skin protection and individualized hand therapy may help daily function. Exercises should suit your circulation, wounds and pain. Avoid forceful stretching across an active ulcer. Tell your team about practical problems such as fastening clothes or opening containers. Softer skin is encouraging, but it does not by itself show that lung or heart monitoring can stop.
The lungs and interstitial lung disease
Lung tests look for changes in lung tissue and follow how well your lungs work, sometimes before symptoms appear.
A high-resolution CT shows lung structure. Breathing tests measure function, including how air moves and how gas passes into the blood. These tests answer different questions. A single number cannot explain every cause of breathlessness; anaemia, heart problems and lung-vessel disease can also contribute.
Treatment may reduce immune activity, slow loss of lung function or combine these aims. Ask what the medicine is intended to achieve and how its effect will be judged. Do not start or increase steroid tablets on your own. New breathlessness, worsening cough or reduced activity deserves contact with your team; sudden severe breathlessness requires emergency help.
Pressure in the lung blood vessels
Pulmonary hypertension means raised pressure in the lung circulation. It has several causes, which need different treatment.
Screening can involve an ultrasound of the heart, breathing tests and blood tests. These help decide whether further investigation is needed. A right-heart catheter test may be needed to confirm the pressure pattern and guide treatment. An ultrasound estimate alone does not establish the full diagnosis.
Specialist treatments have expanded, but a medicine for pulmonary arterial hypertension is not automatically suitable for every kind of lung pressure problem. Report increasing breathlessness, dizziness on exertion, fainting or leg swelling. Do not wait for an annual screening appointment if your condition changes. Fainting with breathing difficulty or chest pain needs emergency assessment.
Heart symptoms and follow-up
The heart can be affected directly or through other conditions. A new symptom deserves a fresh assessment.
Your clinician may recommend an ECG, an ultrasound, blood tests, a rhythm monitor or cardiac MRI depending on the question. These investigate different aspects of the heart. An abnormal blood marker is not a diagnosis by itself, and a normal previous ultrasound does not rule out a new rhythm problem.
Describe palpitations, chest discomfort, ankle swelling, dizziness and changes in exercise tolerance. Note when symptoms occur and how long they last. Sudden chest pain, fainting, severe breathlessness or sustained palpitations with weakness requires urgent help. Treatment depends on the cause and may involve a cardiologist alongside your rheumatologist.
Kidneys and when to get urgent help
A sudden blood-pressure rise or kidney problem can be an emergency in systemic sclerosis.
Ask whether you should check blood pressure at home, how to do it and which change should prompt a call. Know your usual readings. A large rise from your own baseline can matter even if it is below a familiar emergency threshold. Renal crisis can occasionally occur without very high pressure.
Severe new headache, vision change, marked breathlessness, confusion or reduced urine, especially with a pressure change, needs urgent assessment. Do not wait to finish a home diary. Tell all clinicians that you have systemic sclerosis and list your medicines, including steroids. Do not start, stop or change blood-pressure or steroid medicines without medical guidance.
Digestion, swallowing and nutrition
Digestive symptoms can come from several different problems. Identifying the mechanism helps protect comfort and nutrition.
Reflux, swallowing difficulty, early fullness, bloating, diarrhoea, constipation and leakage deserve discussion. Keep track of weight and whether eating has become harder. Smaller meals, adjusted timing or texture may help some people, but very restrictive diets can reduce nutrition. A dietitian can help preserve energy and protein intake.
Progressive swallowing trouble, unexplained weight loss or persistent vomiting needs assessment. Vomiting blood, black tarry stools, or severe abdominal pain with swelling, vomiting and inability to pass gas or stool needs urgent care. Do not treat severe obstructive symptoms with repeated laxatives at home. Medicines, endoscopy and nutrition support are chosen for the actual problem.
Making sense of treatment choices
The best treatment plan names the problem being treated, the expected benefit and how safety and response will be checked.
Different medicines target immune activity, fibrosis, circulation, reflux or other symptoms. A drug can help one organ without treating every aspect of systemic sclerosis. Some treatments are widely used on the basis of evidence even when the US label does not name systemic sclerosis; your clinician should explain the reason for use.
Ask about common side effects, serious problems that need contact, tests, pregnancy considerations and what happens if treatment is not tolerated. Never copy another person’s regimen. Stem-cell transplantation is appropriate only for carefully selected patients in specialist centres; CAR-T is an evolving research approach, not routine treatment for everyone.
Following your condition over time
Monitoring compares your current condition with your own baseline and checks treatment safety.
Visits may review breathing, circulation, skin, weight, digestion, blood pressure, kidney function and medication effects. The schedule depends on your disease pattern and treatment. A repeat test is most useful when everyone knows which question it is answering. Stable results may be a good outcome when the aim is to prevent worsening.
Bring a medication list, the dates of important tests and a brief description of what changed. Ask who receives results and when to contact the team. An appointment months away is not a reason to ignore new symptoms. Our visit planner helps organize information; it does not decide which tests you personally need.
Fatigue, pain and everyday life
Your ability to eat, move, work, sleep and participate in life is part of care.
Fatigue can have several contributors, including sleep, anaemia, nutrition, medicines, mood and heart or lung problems. Pain may come from joints, wounds, poor circulation or other causes. Explain what the symptom prevents you from doing, rather than only giving it a number.
Individualized activity, pacing, hand therapy and practical equipment can help. Ask about mouth-opening difficulties, dental care, sexuality and appearance concerns; these are legitimate parts of a visit. A new major change in strength or stamina deserves reassessment. Choose one achievable functional goal to follow alongside medical tests, such as preparing a meal or walking a familiar route.
Pregnancy, life stages and procedures
Planning ahead makes it easier to align treatment with pregnancy, surgery, dental work and other life needs.
Discuss pregnancy before trying to conceive so your team can review organs and medicines. Some conditions, particularly pulmonary arterial hypertension or severe organ disease, make pregnancy very high risk. Do not stop all medicines independently. Ask about contraception, breastfeeding and fertility when relevant.
Before an operation, explain any limited mouth opening, reflux, lung or heart problems and your medications. Children need specialist care that considers growth and development. Keep up with recommended cancer screening and report concerning symptoms. An antibody associated with cancer risk is not a cancer diagnosis; any additional testing should fit your own clinical picture.
Scleroderma overlap syndromes
An overlap means there are meaningful features of another autoimmune disease alongside systemic sclerosis.
Examples of questions your doctor may investigate include inflammatory muscle weakness, a separate inflammatory arthritis or Sjögren’s disease. An additional antibody or a single symptom does not automatically mean you have another diagnosis.
This chapter gives an overview and helps you find the relevant disease block. More detailed explanations belong in the dedicated muscle, Sjögren’s and other disease sections. Ask which additional findings have actually been confirmed and whether they change treatment or monitoring. Care still needs to account for the systemic-sclerosis pattern even if the other condition becomes the main concern.
Morphea and localized scleroderma
Morphea is a separate condition from systemic sclerosis, but deeper or strategically located lesions can still need substantial treatment.
Morphea can affect skin and sometimes deeper tissues. A line of disease across a joint can limit movement; in a child it may affect growth. Changes on the face or scalp can require specialist evaluation beyond the skin. It is not considered a usual first stage of systemic sclerosis.
Treatment depends on whether disease is active, how deep it extends and what function is at risk. Creams, light treatment or systemic medicines may be appropriate in different situations. Established colour change or tissue loss may need a different approach from active inflammation. Tell your team about new lesions, extension, pain or reduced movement.
When skin thickening has another cause
Several conditions can make skin feel thick or tight. The pattern and other findings help establish the cause.
Your clinician may consider localized skin disease, inflammation around muscles, diabetes-related hand changes, or other uncommon conditions. Blood tests, imaging or a skin or deeper-tissue biopsy may be helpful when chosen for a specific question. Finding fibrosis in a sample is not, by itself, a complete diagnosis.
Tell your team about the timing and distribution of changes, medication or treatment exposures, kidney disease and other health conditions. Ask for a plain-language explanation if the diagnosis is uncertain. Different causes require different care, so clarification can be more helpful than assuming that every tight-skin condition follows the same treatment pathway.
Research and new treatment possibilities
Research is expanding treatment options, but a promising result and a treatment suitable for you are different steps.
Scientists study how blood vessels, immune cells and tissue scarring interact. Some treatments aim to reduce immune activity; others aim to slow fibrosis or improve circulation. A study may show benefit for one organ without proving that the entire disease is cured.
Cell therapies, including CAR-T, are being studied in selected patients. Ask whether a proposal is established care or research, what is known about benefit and risk, and what follow-up is required. Small early studies cannot answer every question about durability or uncommon harms. A trial listing may change over time; participation requires current eligibility assessment and informed consent.
Experimental treatments and future possibilities
Promising research offers possibilities, but benefit, safety and availability must be established for each treatment.
What does “experimental” mean?
A treatment is still being tested for a particular use. A small study can identify a useful signal without proving that it works better than current care. Approval for another illness does not establish benefit in systemic sclerosis. Research participation may help answer important questions without helping every participant. [16]
CAR-T and stem-cell transplantation
CAR-T changes immune cells to target other cells involved in autoimmunity. Early SSc studies have reported improvements, but the number treated is small and long-term risks remain uncertain. Treatment can cause serious immune reactions, infections and low blood-cell or antibody levels. The latest safety information matters as much as the early results. Two major CAR-T trial records checked on 25 September 2026 were not recruiting. [7] [8] [10] [11]
Autologous blood stem-cell transplantation is different: it is already considered for carefully selected people with severe disease at experienced centres. Its risks can be substantial. Neither approach is equivalent to commercial “stem-cell” injections advertised as regeneration. [9] [2]
New medicines and lung fibrosis
Researchers are testing more specific ways to alter immune signalling, including anifrolumab, and ways to slow scarring. Some promising ideas fail in larger trials. An important distinction: nerandomilast already has US approval for adults with progressive pulmonary fibrosis. That lung indication does not mean it treats every form or manifestation of scleroderma. Suitability and availability depend on the individual situation and country. [12] [13] [14]
What might improve in future?
The goals include choosing treatment more accurately, preventing organ damage earlier and achieving lasting benefit with fewer harms. Tissue and immune studies may help, but they do not yet offer a reliable forecast of which experimental treatment will work for you. There is no established date for a universal cure. [15]
Questions before joining a study
Ask what is known, what remains uncertain, whether you might receive a comparator or placebo, and which usual treatments can continue. Clarify serious risks, follow-up, travel and costs, who to contact and what happens if you withdraw. Confirm that the study is currently enrolling. Do not stop prescribed treatment to pursue research without an agreed plan. A registry listing or a paid regenerative package is not proof of benefit. [16] [17]
Sources & further reading
- NIAMS patient information on diagnosis, treatment and living with scleroderma
- British Society for Rheumatology guideline for systemic sclerosis, 2024
- EULAR treatment recommendations, 2023 update published 2024–2025
- ACR/CHEST guidelines for screening, monitoring and treatment of SARD-ILD
- S2k guideline on diagnosis and treatment of localized scleroderma, 2024
- EULAR recommendations for non-pharmacological management of SSc and SLE
- CD19-targeting CAR-T in diffuse SSc, 2025
- CASTLE: phase 1/2 CD19 CAR-T basket trial, Nature Medicine, 2026
- SCOT randomized transplantation trial
- Rapcabtagene autoleucel versus rituximab in diffuse SSc: NCT06655896; registry checked 25 September 2026
- BREAKFREE-1: CD19 CAR-T in refractory autoimmune diseases, NCT05869955; registry checked 25 September 2026
- DAISY: anifrolumab in systemic sclerosis, phase III; sponsor record verified September 2026
- RESOLVE-1: lenabasum phase 3 randomized trial, 2023
- FDA: Jascayd (nerandomilast) approval for adults with progressive pulmonary fibrosis
- Skin tissue remodeling after CD19 CAR-T: mechanistic study, Nature Communications, 2026
- ClinicalTrials.gov: how to join a study and questions for the research team
- FDA: patient information about unapproved regenerative medicine therapies